Notice |
How to write your comments onto a webpage
[2]
| 2016.07.06 | 운영자 | 2016.11.20 | 18142 |
Notice |
How to Upload Pictures in webpages
| 2016.07.06 | 운영자 | 2018.10.19 | 32271 |
Notice |
How to use Rich Text Editor
[3]
| 2016.06.28 | 운영자 | 2018.10.19 | 5860 |
Notice |
How to Write a Webpage
| 2016.06.28 | 운영자 | 2020.12.23 | 43789 |
8840 |
[시조]懷古歌: 회고가
[1] | 2024.04.21 | 정관호*63 | 2024.04.21 | 7 |
8839 |
부산형무소 살해사건
| 2024.04.20 | 온기철*71 | 2024.04.20 | 13 |
8838 |
김구의 일생과 암살의 원인
| 2024.04.14 | 온기철*71 | 2024.04.14 | 17 |
8837 |
코너킥으로 웃었다... 황선홍호, 일본 제압하고 8강으로
[4] | 2024.04.22 | 황규정*65 | 2024.04.22 | 17 |
8836 |
육군 방첩대. 미군 CIC, 그리고 김창룡
| 2024.04.17 | 온기철*71 | 2024.04.19 | 18 |
8835 |
OPERA MIGNON: Connais tu le pays
[1] | 2024.04.12 | 정관호*63 | 2024.04.12 | 23 |
8834 |
레슬링 김현우, 판정 논란 딛고 ‘값진 동메달’ 획득
[1] | 2016.08.14 | 황규정*65 | 2016.08.14 | 26 |
8833 |
“쏘니,너와 함께 뛴건 행운!”, 400경기 감동 축하영상
[5] | 2024.04.06 | 황규정*65 | 2024.04.22 | 29 |
8832 |
길에서 만난 한식
[1] | 2024.04.03 | 정관호*63 | 2024.04.09 | 29 |
8831 |
김정환, 펜싱 남자 사브르 동메달 수확
[1] | 2016.08.10 | 황규정*65 | 2016.08.10 | 30 |
8830 |
‘김신욱 멀티골’ 신태용호, 자메이카와 2-2 무승부
[2] | 2018.01.29 | 황규정*65 | 2018.01.29 | 30 |
8829 |
[평창 올림픽] 이상호, 스노보드 평행대회전서 첫 은메달
[1] | 2018.02.23 | 황규정*65 | 2018.02.23 | 30 |
8828 |
[WC] '손흥민·문선민 골' 축구대표팀, 온두라스에 2:0 승리
[3] | 2018.05.28 | 황규정*65 | 2018.06.03 | 30 |
8827 |
김정은에 대한 최근 News
| 2020.04.25 | 운영자 | 2020.04.25 | 30 |
8826 |
손흥민, 투입 후 17초 만에 도움…토트넘 완승 견인
[2] | 2020.11.06 | 황규정*65 | 2020.11.13 | 30 |
8825 |
한국 여자축구,우즈벡 잡고 2018 아시안컵 본선 티켓 획득
[1] | 2017.04.11 | 황규정*65 | 2017.04.11 | 31 |
8824 |
[평창 올림픽] ‘빙속여제’ 이상화, 여자 500m 은메달 획득
[4] | 2018.02.17 | 황규정*65 | 2018.02.19 | 31 |
8823 |
[평창 올림픽] 차민규, 빙속 男 500m서 깜짝 은메달
[1] | 2018.02.18 | 황규정*65 | 2018.02.18 | 31 |
8822 |
[평창 올림픽] 황대헌, 男쇼트트랙 500m 은메달,임효준은 동메달
[1] | 2018.02.22 | 황규정*65 | 2018.02.22 | 31 |
8821 |
[EPL] 팀 순위도 개인 기록도…소중한 손흥민의 PK
[3] | 2021.04.25 | 황규정*65 | 2021.04.26 | 31 |
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
List of authors.
Abstract
BACKGROUND
Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.
METHODS
We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018–2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.
RESULTS
A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.
CONCLUSIONS
Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.)(NEJM July 8, 2020)